Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

RSV Vaccine Candidate Granted Fast-Track Status for Seniors
RSV Vaccine Candidate Granted Fast-Track Status for Seniors
Denmark-based Bavarian Nordic A/S announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for MVA-BN RSV, a vaccine candidate for active immunizati...
Novo Nordisk gets NICE okay for obesity drug Wegovy
Novo Nordisk gets NICE okay for obesity drug Wegovy
Novo Nordisk’s new obesity therapy Wegovy has been recommended for routine NHS use by UK cost-effectiveness watchdog NICE, but in a narrower group of patients than is covered by its MHRA-approve...
Bayer Receives U.S. FDA Fast Track Designation for asundexian Stroke Program
Bayer Receives U.S. FDA Fast Track Designation for asundexian Stroke Program
Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment for secondary...
New antiviral drug combination is highly effective against SARS-CoV-2, study finds
New antiviral drug combination is highly effective against SARS-CoV-2, study finds
Researchers have identified a powerful combination of antivirals to treat COVID-19. Combining the drug brequniar with remdesivir or molnupiravir -- both approved by the U.S. Food and Drug Administ...
Qurient Announces U.S. FDA Clearance of IND Application for Q901, a Novel Cancer Therapy
Qurient Announces U.S. FDA Clearance of IND Application for Q901, a Novel Cancer Therapy
Qurient Co. Ltd., a clinical stage biotech company, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for Q901, a small mol...
Anti-Microbial Nasal Spray Effective Against COVID-19 in Nonhospitalized Patients, Study Shows
Anti-Microbial Nasal Spray Effective Against COVID-19 in Nonhospitalized Patients, Study Shows
Glenmark Pharmaceuticals reported that its anti-microbial nitric oxide nasal spray (NONS) had positive results in a phase 3 trial in 306 nonhospitalized adult Indian patients with COVID-19. ...
Lupin’s Generic Bronchoconstriction Medicine Gains FDA Approval
Lupin’s Generic Bronchoconstriction Medicine Gains FDA Approval
Indian generic drugmaker Lupin got FDA approval for its nebulization-only medicine for long-term maintenance of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), in...
FDA may halt approval on cancer drugs developed in China
FDA may halt approval on cancer drugs developed in China

Drugs produced in China account for a significant share of the US market. 

Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA
Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA
Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that VCN Biosciences, S.L.'s (VCN) V...
Texas’ $225 million opioid settlement is biggest to date for generic drugmaker
Texas’ $225 million opioid settlement is biggest to date for generic drugmaker

The deal includes $150 million of cash payments over 15 years and $75 million of the overdose-fighting medication Narcan (Naloxone).

Drug halts immune reactions to save damaged lungs
Drug halts immune reactions to save damaged lungs
A team of scientists led by Cold Spring Harbor Laboratory (CSHL) have discovered that disulfiram, an FDA-approved drug, prevents the immune system from producing toxic webs known as neutrophil ext...
Valneva, Pfizer Lyme disease vaccine candidate to enter Phase 3 testing following positive immune showings
Valneva, Pfizer Lyme disease vaccine candidate to enter Phase 3 testing following positive immune showings
Phase 2 testing of a Lyme disease vaccine candidate, VLA15, produced strong immune responses, according to the newest data from Valneva SE and Pfizer inc, prompting preparations for a Phase 3 study...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand